Understanding Organ Rejection: The Immunological Barrier

Organ rejection remains the central challenge in transplantation medicine. When a foreign organ is implanted, the recipient’s immune system recognizes non-self molecules — primarily human leukocyte antigens (HLAs) expressed on donor cells — and mounts a destructive response. This process can be rapid (hyperacute rejection, occurring within minutes due to pre-existing antibodies) or delayed (acute cellular rejection mediated by T cells and chronic rejection driven by ongoing inflammation and fibrosis). Even with careful HLA matching between donor and recipient, the genetic diversity of the human population means that perfect matches are rare. The lifelong reliance on immunosuppressive drugs to manage rejection carries severe side effects, including increased risk of infections, malignancies, and metabolic disorders. Gene editing offers an alternative: instead of suppressing the immune system broadly, we can modify either the donor organ or the recipient’s immune cells to create immunological compatibility at the molecular level.

Gene Editing Techniques in Transplantation

The advent of CRISPR-Cas9 has revolutionized the ability to make precise, targeted changes to the genome. However, transplantation research also employs newer tools such as base editors (which change a single DNA base without introducing double-strand breaks) and prime editors (which can insert small sequences). Each platform has advantages: CRISPR-Cas9 is efficient for gene knockouts, while base editors reduce the risk of off-target indels. In the context of organ compatibility, these tools are used to delete or modify genes that encode immunogenic epitopes or to insert genes that promote immune tolerance.

Editing Donor Organs: Creating Universal Grafts

One promising strategy is to engineer donor organs that are “invisible” to the recipient’s immune system. For human organs, researchers are exploring the knockout of genes encoding major HLAs. Since HLAs are encoded by multiple genes (HLA-A, HLA-B, HLA-C, and others), simultaneous editing is required. In 2019, a team at Harvard demonstrated that CRISPR could be used to delete the β2-microglobulin gene (which is essential for HLA class I expression) in pig cells, a key step toward producing clinically safe xenotransplants. More recently, efforts have focused on pigs genetically modified to remove three major sugar antigens (α-Gal, Neu5Gc, and Sd(a)) that trigger hyperacute rejection. The first pig-to-human heart transplant in 2022 used a pig with 10 gene edits: four gene knockouts to remove pig antigens, plus six human transgenes (including CD55, CD46, and thrombomodulin) to mitigate coagulation and complement activation. Although the patient survived only two months, the experiment proved that gene editing can dramatically reduce the immediate immune response. Future iterations aim at creating a “universal donor” pig that could be used for any patient with minimal immunosuppression.

In parallel, researchers are developing methods to edit human deceased donor organs ex vivo. By perfusing the organ with a CRISPR solution during machine preservation, it may be possible to knock out key HLA genes or introduce protective factors before transplantation. This approach avoids the ethical hurdles of germline editing and allows organ banks to stock a limited set of HLA-depleted grafts.

Modifying the Recipient’s Immune System: Engineering Tolerance

Rather than altering the donor organ, another strategy is to edit the recipient’s own immune cells to tolerate the foreign tissue. This concept builds on established techniques such as bone marrow transplantation for inducing mixed chimerism and tolerance. With CRISPR, it is now possible to precisely edit T cells to reduce their reactivity against donor HLAs. For example, knocking out the T cell receptor (TCR) components or deleting specific co-receptors can render T cells unable to recognize mismatched HLAs. However, such broad changes might also impair protective immunity. A more refined approach uses genetic engineering to create regulatory T cells (Tregs) that actively suppress rejection. Clinical trials are underway using CRISPR-edited T cells that are redirected to recognize donor antigens and produce anti-inflammatory cytokines.

Another cutting-edge concept involves editing hematopoietic stem cells (HSCs) in the recipient so that they give rise to blood cells that are compatible with the donor organ. By inserting donor HLA genes into HSCs, the recipient’s immune system could be “re-educated” to accept the graft as self. This approach, sometimes called immune camouflage, has shown promise in animal models of kidney and heart transplantation. It also holds the potential to reduce or eliminate the need for lifelong immunosuppression, dramatically improving quality of life for transplant recipients.

Current Research and Clinical Progress

The field has moved rapidly from bench to bedside. In addition to the landmark pig heart transplant, a gene-edited pig kidney was transplanted into a brain-dead human recipient in 2023, showing normal function and no signs of hyperacute rejection for 77 hours. Meanwhile, human clinical trials using CRISPR-edited immune cells are already underway for cancer (CAR-T cells) and blood disorders (sickle cell disease). The first clinical trial for CRISPR-edited Tregs in transplantation is expected to launch in Europe within the next two years, focusing on kidney transplant recipients. Regulatory bodies such as the FDA have issued guidance on xenotransplantation and gene editing, requiring rigorous long-term monitoring for off-target effects and zoonotic infections. A recent detailed review published in Nature Reviews Nephrology (2024) outlined the current pipeline of gene-edited organ projects, noting that at least five biotechnology companies are developing universal donor pigs for clinical use.

Challenges and Ethical Considerations

Despite the promise, significant hurdles remain. Technical challenges include achieving high editing efficiency across all cells in a solid organ. Mosaic editing — where only some cells are modified — can leave residual immunogenic epitopes that trigger rejection. Off-target mutations, though reduced by improved editing tools, still pose a risk of unintended oncogenic activation or loss of essential genes. In xenotransplantation, there is also the risk of porcine endogenous retroviruses (PERVs) being transmitted to human recipients. CRISPR has been used to inactivate PERVs in pig cells, but long-term safety data are lacking.

Ethically, gene editing in transplantation raises concerns about equity and access. If gene-edited organs become a premium therapy, they may exacerbate healthcare disparities between wealthy and underserved populations. Additionally, the possibility of using germline editing to create immunological compatibility in future generations remains highly controversial. National academies of science have called for a moratorium on heritable human genome editing for enhancement, but germline edits for disease prevention (such as making a fetus’s immune system tolerant to a potential donor) occupy a gray area. Public engagement and regulatory oversight will be essential to ensure that the technology is deployed responsibly.

Future Directions

Looking ahead, gene editing will likely combine with other technologies to create an entirely new framework for transplantation. The generation of induced pluripotent stem cells (iPSCs) from a patient’s own cells, combined with CRISPR to create universal donor lines, could provide an unlimited supply of matched tissues. Researchers are already growing miniature organs (organoids) from gene-edited stem cells for testing drug compatibility. In parallel, advances in delivery — such as lipid nanoparticles and viral vectors with enhanced tropism — are making it possible to edit cells within the body without removing them. This could allow in vivo editing of a recipient’s liver or kidney to become tolerant before receiving a transplant.

Finally, the convergence of gene editing, machine perfusion, and artificial intelligence will enable personalized organ repair. For example, a donor organ could be scanned for genetic mismatches, edited during hypothermic perfusion, and then validated before implantation. The ultimate vision is a world where organ rejection is a historical curiosity, and transplants are no longer limited by donor shortages or immunological barriers. While challenges persist, the rapid pace of innovation suggests that gene-edited organs will become a clinical reality within the next decade.

Further reading: For an in-depth technical review, see Nature Reviews Nephrology (2024) on gene-edited organs. For xenotransplantation updates, refer to the FDA Xenotransplantation Guidance. Information on clinical trials using CRISPR in transplantation can be found at ClinicalTrials.gov (search “CRISPR transplantation”).